Genetic Technologies Files New Patent Infringement Suit in USA

Genetic Technologies Limited GENE wishes to advise that on May 25, 2011 it filed suit in the U.S. District Court for the District of Colorado, asserting infringement of its primary non-coding patent against the following parties: Agilent Technologies Inc.; Bristol-Myers Squibb Company; Eurofins STA Laboratories Inc.; GlaxoSmithKline PLC; Hologic Inc.; Merial L.L.C.; Navigenics Inc.; Neogen Corporation; Pfizer Inc.; and 454 Life Sciences Corporation. The new suit is in addition to a six-party suit filed in January 2011 in the U.S. District Court for the Western District of Texas for infringement of the same technology. Both suits follow on from the highly successful first assertion program which commenced in February 2010 and concluded in April 2011 (refer ASX announcements dated February 16, 2010 and April 13, 2011, respectively). Akin to the first suit, the new cases will be prosecuted by the Company's Colorado based law firm Sheridan Ross P.C. and, due to arrangements previously put into place, should not have a material adverse impact on Genetic Technologies' finances. Indeed, since the time of filing of the first assertion suit, Genetic Technologies has secured approximately $14.5 million in overall licensing revenues.